A recent recommendation from the CIMPACT-NOW is to designate diffuse, grade II or III, IDH-wildtype astrocytomas with molecular features of GBM directly as “Glioblastoma, IDH-wildtype.” 11. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).